Posts With Tag pharmaceuticals

Explore Regeneron Pharmaceuticals' 8-K filing from October 6, 2025, detailing significant events, stock info, and investor insights.

A rally in drug stocks has driven the Dow and S&P 500 to record highs, showcasing resilience in healthcare despite economic challenges like a government shutdown.

Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.

AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.

Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.

AstraZeneca PLC's August 2025 report corrects a TR-1 notification error. Shareholders should refer to the proper TR-1 from 21 August. Find details on their investor relations site.

Explore AstraZeneca PLC's August 2025 6-K report detailing Capital Group's voting rights change, reflecting shareholder dynamics and compliance with SEC regulations.

Explore AstraZeneca's August 2025 Form 6-K detailing an insider share sale by CFO Aradhana Sarin. Key transaction insights and compliance with EU regulations included.

AstraZeneca PLC's latest 6-K report reveals The Capital Group's increase in voting rights to 5.01%. Insights on shareholder dynamics and corporate governance implications included.

Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.

Explore the impact of Eli Lilly's weight-loss pill on the stock market. Analyze risks, competitors, and investment opportunities in the evolving pharmaceutical landscape.

Explore Gilead Sciences' Q2 2025 financial report showcasing revenue growth in HIV therapy. Key insights on profitability, expenses, and market outlook for informed investment decisions.